Our community has been promised for decades that “one day in the future” there will be treatments for FSHD, and so it’s amazing to realize that day is almost upon us. The future is NOW for clinical trials. In 2019, we saw two Phase 2 trials—for Acceleron’s ACE-083 and Fulcrum’s ReDUX4 (losmapimod). A dozen biopharma companies and academic groups are working hard on the next wave of therapies, and we anticipate more clinical trials over the next few years. It’s very important that we use what we have learned so far to speed up the process and get treatments to our families as soon as possible!
Bottom line: we need to double the number of patients who are actively engaged, especially younger and moderately affected individuals. While companies are investing millions of dollars into research and trials, they can’t succeed without us. Our community must engage fully with the process. Across all research, 85 percent of trials face delays and 30 percent never even get off the ground because of the shortage of volunteers. This dramatically slows research, which means our families must wait longer for treatments.
This summer, Fulcrum Therapeutics launched its Phase 2 ReDUX4 trial of losmapimod, the first drug designed to slow or stop the progression of symptoms. In the lead up to this trial, Fulcrum conducted a “feasibility trial” to validate the methods it hoped to use in the drug trial. We helped to recruit volunteers by sending emails to patients in the vicinity of the research centers involved in the study. We contacted nearly 700 patients and family members, and some 100 people responded. In the end, the study enrolled around 20 volunteers, just enough to complete the study, but it took several months longer than anticipated.
Why was it so difficult for this critical study to recruit enough patient? Researchers need a well-defined population in order get a good signal from a study or trial. If patients are too diverse in their age, disease severity, etc., this can make the data difficult to interpret. For this reason, volunteers had to pass through many hoops to qualify. They had to be the right age. They had to be willing and able to complete multiple visits to the clinic over several months. They needed to be moderately affected—not too little, but also not too much. They had to have a leg muscle that shows up on an MRI as having high water levels (indicating inflammation and DUX4 activity). They needed to be willing to have two muscle biopsies of that muscle (one at the beginning and one at the end of the trial), because this is the only method currently available to show that the drug reduces DUX4 expression.
Given these complexities, it’s easy to understand why only one in 5 would-be volunteers qualified for the study. The ReDUX4 clinical trial is now under way and must recruit 66 volunteers, who must all pass through the same stringent requirements. Every study and drug trial will face similar challenges. And this is why we need many more of you—patients and family members—to be actively engaged and join our “standing army” that is ready to leap into action.
The time is now. The need is urgent. Here’s what you can do:
- Join our contact registry for research;
- Make sure our emails to you aren’t going into junk mail folders;
- Read our e-newsletters and alerts to keep yourself up to date.
Learn how your contribution to our year-end campaign helps to speed up clinical trials.
José Benito Infante del Toro says
November 19, 2019 at 5:19 amHi, I’m from Spain. I live in Palma de Mallorca. I am 33 years old. Currently, I’m slow and I have trouble climbing stairs but I climb them. If I serve you for something, count on me. I work as a nurse in the Oncology plant at the Son Espases University hospital. Thank you.
jkinoshita says
November 19, 2019 at 3:40 pmThere will be trials of the Fulcrum drug in Valencia and Barcelona, Spain. We hope you’ll volunteer!
Jim says
November 19, 2019 at 9:56 amUntil we get to the point of being able to measure DUX4 activity via blood samples, needle muscle biopsies are likely to be part of anti-DUX4 trials for at least the near future.
Patients shouldn’t let a needle muscle biopsy influence their participation in a trial or study without fully understanding a needle muscle biopsy.
A needle muscle biopsy is nothing like the open muscle biopsies many patients have undergone in the past.
A needle muscle biopsy is not nearly as invasive as an open muscle biopsy. With a needle muscle biopsy, the target area is shaved, numbed and a very tiny cut is made in the skin over the target muscle (a few millimeters). A thin needle is inserted one or more times to extract very small amounts of muscle which have been described as the size of a few grains of rice. The patient may feel a slight tugging or a small amount of discomfort, but generally no significant pain. Even in diseased muscle, this small amount of muscle is expected to regenerate.
Sterile dressing is applied to the area which can be removed in a day or two. In most patients, any pain is minimal and normal activity can resume in a day or two. In most cases, no lasting scar or mark remains after a month or two post biopsy.
If a needle muscle biopsy has been preventing you in participating in any studies, please talk to your study doctor to learn more about the procedure including all risks.
Teresa says
November 21, 2019 at 6:58 pmHi Jim,
I live in the Northern Virginia(loudoun county) area outside of DC. I am interested in learning more about this clinical trial but like most hesitant with the biopsy of the muscle. In my 30’s, can walk but developed drop foot on my right side in recent years, now wearing AFOs. Been fully diagnosed with FSHD. Would you pls direct me to where I can go and call to learn more about the process in my area. I would greatly appreciate it.
Jim says
December 1, 2019 at 8:43 amHi Teresa.
That is great that you are considering the Fulcrum trial. Yes, please learn more about a needle muscle biopsy and decide if that is an agreeable procedure for you and if your condition meets other trial requirements.
The clinicaltrials.gov web page for the trial is:
https://clinicaltrials.gov/ct2/show/NCT04003974?cond=fshd&draw=2&rank=1
Here are some study locations close to Loudon County.
The study coordinator at the Virginia Commonwealth University in Richmond is:
Nicholas Johnson, MD 804-828-9350 nicholas.johnson@vcuhealth.org
The study coordinator at Kennedy Krieger Institute in Baltimore is:
Genila Bibat, MD 443-923-2697 bibat@kennedykrieger.org
Allan Etheridge says
November 20, 2019 at 4:52 pmWish there where more trials in th uk
Arvid Karlsen says
November 22, 2019 at 2:49 amACE-083? Has not that been given up?
jkinoshita says
December 2, 2019 at 1:13 pmDevelopment of ACE-083 has been halted, but the fact that a Phase 2 trial was done is an important achievement. While a clinical trial that does not prove the efficacy of a drug is often said to have “failed,” that is a misnomer. It is a successful trial if it resulted in a clear, actionable outcome (go or no-go). A failed trial is one that could not be completed (for example because it could not recruit enough volunteers, or the data were of poor quality and did not produce a clear conclusion).
Joshua McDonald says
November 28, 2019 at 3:35 amI want to know why we need muscle biopsied when there are better ways to detect the effectiveness of the treatment. Invasive testing like this should be a last resort. Also, knowing how big the biopsy would be makes a huge difference. Many of us have little to no muscle left, a biopsy of 1% of a normal muscle could be 90% of ours.
jkinoshita says
December 2, 2019 at 1:17 pmAt this time, there is no other way to show that a drug has inhibited DUX4 expression in the muscle than to biopsy the muscle. Researchers are working to validate less-invasive tests, such a blood test, by collecting both biopsies and blood samples from patients and then seeing if the levels of certain molecules in the blood correlate with the changes in DUX4 expression seen in the biopsy. The biopsies needed for the Fulcrum trial are about the size of a grain of rice and can be done with a needle.
Gajin Kunwar says
November 30, 2019 at 12:58 amI live in Sydney. I am originally from Nepal. I am interested in learning more about this clinical trial. In my 30’s, can walk but developed drop foot on my both side in recent years, now wearing AFOs. Been fully diagnosed with FSHD
scott patterson says
December 1, 2019 at 4:03 pmhi there, I living in Queensland in Australia and just wondering if there is any trial happening or will be in the near future?
oscar says
December 1, 2019 at 4:06 pmHola estoy espectante para el ensayo de losmapimod, cuando se abra en España, espero poder participar. Soy de Madrid y estoy diagnosticado de FSH.
Gerda Brown says
December 2, 2019 at 12:19 amI am the National General Manager for the Muscular Dystrophy Foundation of South Africa and is also affected by FSH. Unfortunately there is hardly any research opportunities in South Africa. Is there any way that we can get involved in your studies?
jkinoshita says
December 2, 2019 at 3:26 pmHi Gerda, Thanks for reaching out. It would be helpful to know how many FSHD patients you have registered with the MDSA, your ability to contact them, and also the existence of clinical research centers that would have the interest and capability to run a study. This would provide a basis on which to bring clinical research and trials to South Africa. We do have a number of patients who have contacted the Society over the years and there’s a limited amount we can do from here without having some kind of infrastructure on the ground there. We’d be happy to discuss further. Please feel free to contact June Kinoshita at june.kinoshita@fshdsociety.org.